Skye Bioscience Inc
skyebioscience.comSkye Bioscience Inc (NASDAQ: SKYE) is a clinical-stage biopharmaceutical company focused on developing drug candidates, with operations subject to oversight under U.S. federal and state regulations including HIPAA and FDA approval processes. The company generates no product revenue as of the fiscal year ended December 31, 2025, operating entirely on equity and debt financing to fund clinical development activities. Leadership includes CEO Punit Dhillon, whose employment agreement dates to August 2020, and the company files as a smaller reporting company with the SEC. Skye Bioscience's patent portfolio is central to its competitive position, with U.S. patents subject to the standard 20-year term and potential extensions under the Hatch-Waxman Amendments. The company is incorporated and operates primarily in the United States, with its principal accounting audited by CBIZ CPAs P.C. and previously Marcum LLP.
Products & Services
The filing excerpts reference drug product candidates subject to FDA regulatory review but do not name specific compounds or therapeutic areas by product name.
Revenue Model
The filing excerpts do not disclose any product revenue or licensing revenue. The company funds operations through equity financing, as indicated by references to dilutive equity and debt financing in the risk factors (10-K, filed 2026-03-10).
Customers & Markets
The filing excerpts do not disclose specific customers, customer concentration, or named end markets.
Geographic Exposure
United States, with references to compliance with U.S. federal and state privacy laws including California, Colorado, Connecticut, Utah, and Virginia (10-K, filed 2026-03-10). Some foreign export and import control obligations noted.
Financial Snapshot
Loading...
